Search results
Jun 19, 2020 · Children and adolescents with ADHD often show a great affinity with digital media, which may improve compliance, but one has to take into account that the rate of problematic internet use and gaming is enhanced in youth with ADHD (estimated at 37% in ADHD vs. 12% in TD).
- Table - PMC - National Center for Biotechnology Information
Generic name Adverse drug reaction; Methylphenidate...
- ADHD in children and youth: Part 1—Etiology, diagnosis, and ...
Current estimates show that 50% of children with ADHD...
- The management of ADHD in children and adolescents: bringing ...
Young children: under 5 years (NICE) or under 6 years...
- Table - PMC - National Center for Biotechnology Information
Feb 17, 2023 · Results: Twenty-three studies were included, with most rated as “good” quality. Meta-analysis found “very large” effect in both parent- (Hedges’ g −1.67, 95% CI [−2.57, −0.78]) and child-reported (Hedges’ g −1.28, 95% CI [−2.01, −0.56]) HRQoL for children with ADHD compared to children without ADHD.
People also ask
Is there evidence for treatment of ADHD in children and adolescents?
What is the prevalence of ADHD in children and young people?
How effective are pharmacological treatments for children and adolescents with ADHD?
Mar 25, 2024 · Effective treatment of attention-deficit/hyperactivity disorder (ADHD) is essential to improving youth outcomes. OBJECTIVES. This systematic review provides an overview of the available treatment options. DATA SOURCES.
May 23, 2024 · ADHD medication treatment patterns varied by some demographic characteristics; a lower prevalence of children aged 3–5 years were taking ADHD medication (23.6%) than older children (56.9% of children aged 6–11 years, 53.4% of adolescents aged 12–17 years); similarly, Hispanic children and children living in non-English-speaking households ...
This Review comprises a systematic review of the community and administrative prevalence of ADHD in children and adolescents; an overview of the barriers to accessing care; a description of costs associated with ADHD; a discussion of evidence-based pathways and the delivery of clinical care, with consideration of specific issues for two age grou...
